Corvus Pharmaceuticals Reports Q3 Loss of $0.22 Per Share
CRVS Corvus Pharmaceuticals Inc
$11.35 +7.69%
View chart & analysis → - 1Corvus Pharmaceuticals missed third-quarter expectations by 4.8%.
- 2Corvus Pharmaceuticals showed an 83.3% increase in losses compared to the same period last year.
- 3Corvus Pharmaceuticals reaffirmed its cash runway guidance through the second quarter of 2028.
So what's the key point?
Corvus Pharmaceuticals reported third-quarter results that were lower than analyst expectations. While losses increased to $0.22, the company stated its cash runway remains unchanged through 2028.
Source Earnings Whispers · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.